e-learning
resources
Amsterdam 2015
Monday, 28.09.2015
Pulmonary hypertension: novel clinical insights
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Rationale and study design of the RESPITE trial: Riociguat clinical effects studied in pulmonary arterial hypertension (PAH) patients with insufficient treatment response to PDE-5 inhibitors (PDE-5i)
Marius M. Hoeper (Hannover, Germany), Marius Hoeper, Raymond Benza, Gerald Simonneau, James Klinger, David Langleben, Robert Naeije, Paul Corris
Source:
International Congress 2015 – Pulmonary hypertension: novel clinical insights
Session:
Pulmonary hypertension: novel clinical insights
Session type:
Poster Discussion
Number:
2110
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Marius M. Hoeper (Hannover, Germany), Marius Hoeper, Raymond Benza, Gerald Simonneau, James Klinger, David Langleben, Robert Naeije, Paul Corris. Rationale and study design of the RESPITE trial: Riociguat clinical effects studied in pulmonary arterial hypertension (PAH) patients with insufficient treatment response to PDE-5 inhibitors (PDE-5i). Eur Respir J 2015; 46: Suppl. 59, 2110
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
The definition of pulmonary hypertension: history, practical implications and current controversies
Related content which might interest you:
RESPITE: Riociguat in pulmonary arterial hypertension patients with an inadequate response to phosphodiesterase type 5 inhibitors
Source: International Congress 2016 – Clinic of pulmonary hypertension
Year: 2016
Time to combination therapy for sildenfail monotherapy in pulmonary artery hypertension (PAH). A comparison with the reported experience with bosentan
Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment
Year: 2013
Initial combination therapy with ambrisentan (AMB) and tadalafil (TAD) in treatment naïve patients with pulmonary arterial hypertension (PAH): Efficacy and safety in the AMBITION study intent to treat (ITT) population
Source: International Congress 2015 – Pulmonary hypertension: new treatment insights
Year: 2015
Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2)
Source: Eur Respir J 2015; 45: 1303-1313
Year: 2015
Effect of macitentan on haemodynamics in SERAPHIN, a randomised controlled trial in pulmonary arterial hypertension (PAH)
Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment
Year: 2013
Riociguat for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH): Final data from a phase II long-term extension (LTE) study
Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots
Year: 2015
Open label study of ambrisentan in patients with exercise induced pulmonary arterial hypertension (EiPAH)
Source: International Congress 2016 – Pulmonary hypertension and pulmonary embolism: from the bench to the bedside
Year: 2016
Effect of riociguat on pulmonary arterial compliance (PAC) in patients with CTEPH in the CHEST-1 study
Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots
Year: 2015
Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2)
Source: Eur Respir J 2015; 45: 1293-1302
Year: 2015
Sitaxsentan treatment for patients with pulmonary arterial hypertension (PAH) failing bosentan due to lack of efficacy
Source: Eur Respir J 2005; 26: Suppl. 49, 476s
Year: 2005
Upfront combination therapy in the treatment of scleroderma-associated pulmonary arterial hypertension: Results of an open label trial
Source: International Congress 2015 – Pulmonary hypertension: new treatment insights
Year: 2015
Effect of selexipag on long-term outcomes in key subgroups of patients with pulmonary arterial hypertension (PAH): GRIPHON study results
Source: International Congress 2015 – Pulmonary hypertension: new treatment insights
Year: 2015
RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors
Source: Eur Respir J, 50 (3) 1602425; 10.1183/13993003.02425-2016
Year: 2017
Initial dual oral combination therapy for pulmonary arterial hypertension (PAH) in daily practice
Source: International Congress 2015 – Pulmonary hypertension: management
Year: 2015
Bosentan delays time to clinical worsening (TTCW) and improves haemodynamics in who class II pulmonary arterial hypertension (PAH) patients: EARLY study results
Source: Annual Congress 2007 - Clinical aspects of pulmonary arterial hypertension
Year: 2007
Change of right heart size and function by long-term therapy with riociguat in patients with PAH and CTEPH
Source: International Congress 2015 – Pulmonary hypertension: the right ventricle and its load
Year: 2015
Item performance of the pulmonary arterial hypertension symptoms and impact (PAH-SYMPACT®) questionnaire: Results from the SYMPHONY study with macitentan
Source: International Congress 2016 – Pulmonary hypertension: the clinic II
Year: 2016
Long-term safety and clinical effects of riociguat in chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: Interim analysis of a phase II extension study
Source: Annual Congress 2010 - Pulmonary hypertension updates
Year: 2010
Riociguat for the treatment of pulmonary hypertension: Safety data from the EXPERT registry
Source: International Congress 2016 – Pulmonary hypertension: the clinic II
Year: 2016
Effect of riociguat on pulmonary arterial compliance (PAC) in patients with PAH in PATENT-1
Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept